氨溴索治疗2019新型冠状病毒肺炎的研究现状

Research status of ambroxol in the treatment of Coronavirus disease 2019

2019年12月,新型冠状病毒肺炎(COVID-19)在湖北武汉爆发,2个月内迅速传遍全国,致死率约达2.1%。对COVID-19患者病例特点的分析及对首例死亡患者的病理解剖表明,急性呼吸窘迫综合征在COVID-19患者病程中起重要作用。氨溴索作为呼吸系统常用药,除祛痰作用外,其在治疗急性呼吸窘迫综合征、肺部纤维化等病理过程中均有良好的临床效果,且最近氨溴索也被发现其可作为血管紧张素转化酶2结合药,有望在COVID-19防治过程中发挥独特的药效。

In December,2019,an outbreak of respiratory disease named as Coronavirus disease 2019(COVID-19),emgerged in Wuhan,China.Unfortunately,it reached mulitiple continents in past two months,with a very high transmission rate and a mortality rate for about 2.1%.The Analysis of the characteristics of patients with COVID-19 infection and the pathologic anatomy of the first case of death suggest that acute respiratory distress syndrome plays an important role in the course of disease in patients with COVID-19 infection.Ambroxol,as a common expectorant drug for respiratory system,also has a good clinical effect in the treatment of acute respiratory distress syndrome and pulmonary fibrosis.Ambroxol has also been recently found to be an angiotensin converting enzyme 2 binding agent,which is expected to play a unique role in the prevention and treatment of COVID-19.